MAIA Biotechnology, Inc. 8-K

What Happened MAIA Biotechnology, Inc. (NYSE American: MAIA) announced results of its May 21, 2026 Annual Meeting of stockholders. A quorum was present. Stockholders re-elected both Class I director nominees to three-year terms (expiring at the 2029 annual meeting) and ratified Grant Thornton LLP as the company’s independent registered public accounting firm for fiscal 2026. The company’s definitive proxy statement was filed April 7, 2026.

Key Details

• Shares outstanding (record date March 23, 2026): 60,671,491; shares present in person or by proxy: 37,547,754 (≈61.88%).
• Director votes:
  • Louie Ngar Yee — For: 16,658,677; Withheld: 8,796,832; Broker non-votes: 11,375,414.
  • Steven Chaouki — For: 25,109,811; Withheld: 345,698; Broker non-votes: 11,375,414.
• Auditor ratification vote: For 37,278,294; Against 210,408; Abstain 19,052.

Why It Matters The meeting outcome confirms continuity of MAIA’s board leadership and the company’s external auditor for the coming year—both governance items investors monitor for oversight and financial reporting reliability. The presence of significant broker non-votes and withheld votes on one nominee are factual voting details investors may consider when assessing shareholder support and governance dynamics.